Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug combo enters first human tests

NCT ID NCT06031441

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 5 times

Summary

This early-stage trial is testing an experimental drug called RO7566802, alone or with the immunotherapy atezolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of activity. About 250 participants will take part in this first-in-human study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RO7566802 (an experimental drug) and atezolizumab (Tecentriq, an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. The drug may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

65 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Life expectancy \>=3 months, in the investigator's judgment * Adequate hematologic and end-organ function * Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care * Measurable disease per RECIST v1.1 * Tumor specimen availability, for certain cohorts Exclusion Criteria: * Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to Cycle 1 Day 1, with certain exceptions * Active hepatitis B or C * Active tuberculosis * Positive test for human immunodeficiency virus (HIV) infection * Administration of a live, attenuated vaccine (e.g., Flumist) within 4 weeks prior to RO7566802 infusion * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * Active or history of autoimmune disease * Prior allogeneic stem cell or organ transplantation * Uncontrolled tumor-related pain * Significant cardiovascular disease Other protocol-defined inclusion/exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced solid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced solid tumors Metastatic solid tumors Recurrent solid tumors

Contacts and locations

Locations

  • Addenbrooke's Hospital

    Cambridge, CB2 0QQ, United Kingdom

  • British Columbia Cancer Agency - 600 10th Ave W

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Churchill Hospital

    Oxford, OX3 7LJ, United Kingdom

  • Icahn School of Medicine at Mount Sinai (ISMMS)

    New York, New York, 10029, United States

  • Leicester Royal Infirmary

    Leicester, LE1 5WW, United Kingdom

  • Magee-Woman's Hospital

    Harrisburg, Pennsylvania, 17109, United States

  • National Cancer Centre

    Singapore, 168583, Singapore

  • National University Hospital

    Singapore, 119074, Singapore

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 1Z5, Canada

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon Research Institute

    London, W1G 6AD, United Kingdom

  • St Bartholomew's Hospital

    London, EC1A 7BE, United Kingdom

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, 2010, Australia

  • The Ohio State University

    Columbus, Ohio, 43221-3502, United States

  • The Royal Marsden hospital

    Sutton, SM2 5PT, United Kingdom

  • University of Alabama at Birmingham (UAB)

    Birmingham, Alabama, 35233, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.